Second Generation 18F-labeled Prostate-Specific Membrane Antigen (PSMA) Targeted Imaging Agent Found to be Highly Sensitive in Detecting Prostate Cancer

Culver City, CA (PRWEB) April 28, 2015 A first-in-human prostate cancer study released today in the Journal of Molecular Imaging and Biology showed initial safety, biodistribution, and dosimetry results with [18F]DCFPyL, a 2nd generation fluorine-18 labeled small-molecule PSMA inhibitor. The imaging biomarker has been developed at Johns Hopkins University in Baltimore, MD by study co-author, ...

AxioMx Receives SBIR Grant to Develop Multiplex Antigen Screening Technology

Branford, Conn. (PRWEB) March 10, 2015 AxioMx Inc., a biotechnology company specializing in the development of high-quality recombinant research antibodies, announced today that the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant (1R43GM112385-01). This Phase I award, which will be administered by the National Institute of General ...